Reimbursed Care Access in Croatia

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Croatian Law on Combating Drug Abuse (Zakon o suzbijanju zlouporabe opojnih droga) lists unauthorised manufacture, possession and trade of controlled psychotropic substances as offences and provides the framework for prosecution or administrative penalties; possession of small quantities for personal use is treated as a misdemeanour since 2013, not a licensed medical pathway. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is not an authorised medicine in routine Croatian practice; any therapeutic use would only be possible within a formally approved clinical trial or via an exceptional authorisation mechanism tied to the national legal framework. #

Esketamine nasal spray (SPRAVATO®) holds an EU marketing authorisation (authorisation issued 18 December 2019) for adults with treatment‑resistant major depressive disorder in combination with an SSRI or SNRI; the product is distributed in EU member states and must be administered under supervision in a healthcare setting per the EMA product information. #.

Regulatory framework and payer position in Croatia: because Spravato is authorised at the EU level it may be supplied in Croatia through the standard national medicines regulatory and distribution channels, and clinical use must follow the EMA/SmPC restrictions (psychiatric prescriber, supervised administration, monitoring of blood pressure). However, national reimbursement (Hrvatski zavod za zdravstveno osiguranje, HZZO) inclusion is determined by HZZO's reimbursement/listing procedures; public reporting indicates that esketamine was considered for placement onto national drug lists and procurement/pricing discussions have been reported to HZZO (reporting of placement decisions appeared in Croatian press reporting HZZO's annual list updates). Where Spravato is not included on the HZZO reimbursed medicines list, access is possible through private payment or individual reimbursement/exceptional funding requests to HZZO, subject to national rules and local hospital/clinic policies. # #.

Practical implications for clinicians and patients: initiation should be by a psychiatrist in a facility equipped for supervised dosing and vital‑sign monitoring (as specified in the SmPC); if public reimbursement is required, clinicians or institutions must follow HZZO procedures for adding high‑cost specialty medicines or submit case‑by‑case funding applications. If you need an authoritative, up‑to‑date statement on whether SPRAVATO® is formally listed on HZZO's reimbursed medicines list (and any reimbursement criteria), I can check HZZO's current medicinal reimbursement lists and the official HZZO decisions and provide direct citations.

Ketamine is an approved and widely used anaesthetic and analgesic in Croatia (legal for licensed medical indications) and is available in hospitals and clinics for surgical and emergency use under standard medicinal regulation. In psychiatry, ketamine (intravenous or intranasal formulations other than esketamine) is sometimes used off‑label for rapid antidepressant effects in specialised private clinics or hospital settings; such use is governed by general prescribing/medical practice rules and is typically not covered as a routine reimbursed indication by public payer schemes unless specifically negotiated or included in HZZO reimbursement decisions. Clinical guidance documents in Croatia mention NMDA‑receptor acting agents (including esketamine) in treatment‑resistant depression pathways, reflecting awareness of glutamatergic agents, but off‑label ketamine infusion clinics operate under standard medical‑prescribing frameworks rather than a specific national, reimbursed psychiatric indication. # #.

Reimbursement and access nuance: routine HZZO outpatient reimbursement for ketamine specifically as an antidepressant indication is not established as a standard benefit; patients seeking ketamine for depression usually do so in private settings or via hospital formularies and may seek exceptional funding if clinically justified.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and plant preparations containing DMT) are subject to the Croatian controlled‑substance framework and may only be handled lawfully in authorised scientific studies or under explicit regulatory exemptions. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, distribution or use outside approved research or specific legal exemptions is prohibited under Croatian law. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Secondary sources and country comparisons list ibogaine as outlawed or restricted in Croatia. Any therapeutic or clinic‑based use would therefore be barred except in formally sanctioned research. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Because ayahuasca preparations commonly contain DMT (a controlled substance), their importation, possession or use is not permitted outside authorised scientific or ethnobotanical research contexts. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and cacti containing it) fall under the national controlled‑substance regime and are not part of routine medical practice or reimbursement. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The broader 2C family of phenethylamine psychedelics are controlled and subject to enforcement under Croatian narcotics law. #